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Abstract
DEVIN HATCHELL. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix
Hemorrhage-Induced Secondary Injury. (Under the direction of STEPHEN TOMLINSON and
RAMIN ESKANDARI).

Germinal Matrix Hemorrhage (GMH) is a devastating neurologic pathology in neonates
that leads to impaired neurodevelopmental processes and approximately 90% rate of morbidity
and mortality within two years in severe cases. Recent studies in our lab have indicated a role
for complement in the initiation and propagation of secondary injury after GMH, which includes
neuroinflammation and hydrocephalus development. Here we investigate a strategy to target
complement inhibition specifically to sites of P-selectin expression, a relevant adhesion
molecule at sites of vascular injury/inflammation, as well as investigate the role of P-selectin in
leukocyte recruitment and the propagation GMH secondary injury. We prepared two fusion
proteins consisting of anti-P-selectin single chain antibodies (scFv) linked to Crry, a complement
inhibitor. One of the scFv targeting vehicles (2.12scFv) additionally blocked the cell adhesion
site of P-selectin, whereas the other (2.3scFv) bound P-selectin without blocking its function.
For our investigations, post-natal mice on day 4 (P4) were subjected to collagenase inducedGMH and treated with 2.3Psel-Crry, 2.12Psel-Crry, or vehicle. Histopathological and behavioral
analyses were performed at P14 and P45. After GMH injury, 2.3Psel-Crry treatment resulted in
reduced infarct size and neurological deficits with improved survival, whereas 2.12Psel-Crry
treatment resulted in worse outcomes compared to vehicle. MRI analyses revealed that 2.3PselCrry also reduced post-hemorrhagic hydrocephalus (PHH) development. We also found that
2.12Psel-Crry, but not 2.3Psel-Crry, had an anti-coagulative effect as determined by increased
bleeding time and decreased heterotypic platelet interactions. P-selectin expressed on platelets
is known to have a pro-coagulative function, and this effect of 2.12Psel-Crry likely explains the
worse outcomes when used to treat this hemorrhagic condition. In summary, we show that GMH
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induces expression of P-selectin, the targeting of which with a complement inhibitor is protective
against secondary neuroinflammation and development of PHH. Although unexpected, the
worsened outcomes with a targeted construct that also inhibits P-selectin function (ie. 2.12PselCrry) can be explained by its effect on interfering with the coagulation cascade. Whereas the
2.3Psel-Crry construct has potential for protecting against the pathogenic sequelae of GMH, the
2.12Psel-Crry construct has promising potential for treatment of conditions that incorporate
pathological thrombotic events, such as ischemic stroke.
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Chapter 1. Introduction
1.1 Germinal Matrix Hemorrhage
Germinal Matrix Hemorrhage (GMH) is the most common neurologic pathology in
neonates, estimated at 3.5 per 1000 live births [1]. The occurrence of GMH rupturing is strongly
associated with pre-term birth (<32 weeks) and low birth weight (<1500 g) [2, 3]. Furthermore, a
greater severity of hemorrhage correlates to a greater risk rate for morbidity and mortality, with
severe cases being accompanied by approximately 90% rate of morbidity and mortality [4]. The
germinal matrix is a cellular and vascular rich structure beneath the ependymal germinal region
where cells migrate out during brain development [5]. GMH is directly caused by disruption of the
fragile cerebral vasculature of the germinal matrix, leading to its development as a periventricular
hemorrhage that subsequently extends into the intraventricular space and parenchymal tissue [6].
Hemorrhagic progression into the ventricles is known as intraventricular hemorrhage (IVH) and
can lead to the development and progression of pathological processes such as post-hemorrhagic
hydrocephalus (PHH) and periventricular leukomalacia (PVL). In addition to the significant impact
GMH has on mortality, it is well established that the progression of GMH leads to altered
neurodevelopmental outcomes as well [2, 7]. With the germinal matrix being the site of origin for
cerebral precursor cells both of gray and white matter, it can easily disrupt the maturation of these
cells in the developing fetal brain. IVH of all grades have the potential to cause reduction in cortical
gray matter, cortical white matter, cognitive function, and motor function; as well as an increase
in cerebral palsy (CP) and mental disability at a later timepoint [8-11].
Currently there are no medical treatments for GMH, and the nature of the pathological
etiology makes it difficult to target therapeutically. One of the limited line of defenses for GMH
involves regulating cerebral blood flow in an attempt to mediate any dysfunctional pressures that
may cause disruption in the fragile vasculature [12, 13]. While this has increased the survival
outcome after GMH and overall birthrate of preterm infants, it has inadvertently caused an
increase in occurrence of the pathological sequalae that follows the rupturing such as PHH [3].
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1.2 Post-Hemorrhagic Hydrocephalus and the Inflammatory Injury After GMH
It has been well established in traumatic brain injury (TBI) and stroke, that the pathological
progression of injury involves a primary insult that is immediate and unpredictable and is followed
by a secondary injury that can be accounted for by an inflammatory response. Similarly, GMH
involves a primary injury that cannot be prevented by intervention due to immediate and
unexpected mechanical trauma of a hemorrhagic mass, that is then followed by a secondary
progressive injury that extends into neighboring tissue [14]. The onset and progression of PHH,
a relevant pathologic sequalae secondary to GMH, is influenced by an inflammatory response
characterized by increased inflammation and cytokine and chemokine release [15-17]. PHH is the
result of progressive dilation of the cerebral ventricular system due to disturbances in
cerebrospinal fluid (CSF) flow or absorption following hemorrhage and is associated with
neurocognitive impairment, motor dysfunction, and growth impairment [18]. Currently, there are
no medical treatments for PHH, only an invasive surgical procedure to allow cerebrospinal fluid
(CSF) diversion to mitigate the effects of PHH by temporarily resolving CSF build up. This method
is effective at mitigating the constant buildup of CSF, but cannot cure the neurological impairment
caused by progressive damage from the hemorrhage [14]. Given the clinical outcome, current
treatment options, and evidence of a secondary inflammatory injury following GMH, there has
been strong evidence to investigate relevant inflammatory drivers and potential immune
therapeutic target in resolving post-GMH pathological sequalae.

1.3 The Complement System
The complement system is a cascading mechanism that consist of over 30 soluble or
membrane-associated proteins [19]. Once the system is activated, complement cleavage
products orchestrate a cascading effect producing inflammatory responses ultimately influencing
innate and adaptive immunity. The complement system is activated in three unique pathways: the
classical, lectin, and alternative pathway. All three of the pathways eventually converge at the C3
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protein where its cleavage produces opsonization fragments (C3b, iC3b, C3d, C3dg), as well as
the anaphylatoxin C3a that influences opsonization of foreign material and injured tissue as well
as immune cell recruitment. Further downstream cleavage within the cascade produces additional
fragments (C5a, C5b, C6-9) leading to additional opsonization, immune cell recruitment, and
formation of the cytolytic membrane attack complex (MAC) [20].
Over the past decade, along with furthering our knowledge of canonical functions of the
complement system, recent studies have uncovered a non-canonical role of complement involved
in producing an ongoing inflammatory response that is implicated in the secondary injury of
multiple pathologies [21-23]. More specifically in the setting of brain injury, evidence supports
complement’s opsonins and anaphylatoxins having a direct role in the phagocytosis of neurons,
edema, cell lysis, and infiltration of inflammatory cells [20, 23-25]. Not until recently has the effect
and role that complement plays in the activation and progression of secondary injury post-GMH
been explored. Alshareef et. al (2022) gives evidence that complement plays a direct role in
astrocytosis, microgliosis, neuronal phagocytosis, and progression of PHH post-GMH [14],
providing evidence and support of complement’s role in propagating post-GMH pathology and the
potential of complement inhibition to be protective.

1.4 P-selectin Role in Vascular Injuries and Inflammation
Injuries to vasculature structure causes endothelial activation and recruitment of surface
proteins as an inflammatory response to clear and repair damaged tissue, this includes a
mechanistic way to recruit circulating leukocytes such as neutrophils. Neutrophil recruitment and
infiltration have been shown to play important roles in the inflammatory response induced by
hemorrhage [26]. Of importance it has also been shown to play roles in post-GMH pathologies in
preclinical models and clinical studies [14, 27-29].
A relevant surface protein that plays a role in the primary phase of this mechanism is the
transmembrane cell adhesion molecule P-selectin. As an integrin receptor, P-selectin binds
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preferentially to ligands on leukocytes as well as on platelets and endothelial cells. The most
characterized and relevant ligand of P-selectin is P-selectin Glycoprotein Ligand-1 (PSGL-1) that
is expressed on leukocytes [30]. In a relevant injury setting, knockout and blockade of P-selectin
led to attenuated leukocyte-endothelium interaction resulting in a reduction in infiltrating
leukocytes [26]. Furthermore, complement activation and P-selectin expression have been shown
to have an integrated relationship. Activation of the complement cascade by itself can upregulate
P-selectin expression and vice versa, P-selectin can directly activate complement [31, 32]. While
both complement inhibition in a GMH model and P-selectin blockade in a hemorrhagic model
have independently been shown to be protective, the concept of P-selectin targeted complement
inhibition in the setting of GMH nor the dual inhibition has been investigated before.

1.5 Advancing therapeutics for GMH and post-GMH sequalae with Complement Inhibition
Given complement’s multiple roles in immune surveillance and homeostatic activities,
systemically inhibiting the cascading system can lead to unwarranted and detrimental effects [20].
To overcome this challenge, recent studies have shown the efficacy of using site-targeted
complement inhibition in models recapitulating neuroinflammatory responses such as stroke and
TBI, as well as GMH [14, 23, 33]. Here we characterize a novel site-targeted complement
inhibiting therapeutic strategy in the setting of GMH that will be targeted specifically at sites of
injury and elucidate its potential in other brain injuries.
The two site targeted complement inhibitors used are fusion proteins consisting of antiPselectin single chain antibodies (scFv) linked to the murine complement inhibitor Crry, namely
2.12Psel-Crry (2.12scFv or the blocking construct) and 2.3Psel-Crry (2.3scFv or the non-blocking
construct). By using the anti-Pselectin scFv targeting moieties, it is expected that the complement
inhibitor will be targeted specifically to P-selectin, where it is expected to be upregulated at sites
of injury and inflammation. More specifically, once targeted to sites of injury, Crry will inhibit C3
convertase, an enzyme responsible for the cleavage of the C3 protein leading to the cleavage
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products C3a and C3b as well as further downstream complement components. Additionally, one
of the scFv targeting vehicles (2.12Psel-Crry) blocks the cell adhesion site of P-selectin, whereas
the other (2.3Psel-Crry) binds P-selectin and will inhibit C3 convertase without blocking its
function. The dual functionality of the 2.12Psel-Crry, gives the potential of site target complement
inhibition as well as limit neutrophil infiltration, therefore limiting the inflammatory response further.
Firstly, this study encompasses using these P-selectin site targeted inhibitors as a
preclinical tool to provide further evidence of complement’s role as well as revealing the role that
P-selectin may play in GMH and its sequalae. Secondly, this study aims to characterize each
inhibitor in its ability as being a neuroprotective agent by limiting neuronal loss, preventing
neurocognitive deficits, and inhibiting the on-set and propagation of post-GMH secondary injury
such as PHH.

Chapter 2. Materials and Methods
Study Design
This study used five animal treatment groups: Wild-type Naïve (no injury and no
treatment), Sham (endotoxin free PBS injection in the SVZ in place of collagenase and no
treatment), Vehicle (Collagenase injection in the SVZ and intraperitoneal PBS treatment), and
Psel-Crry treated (Collagenase injection in the SVZ and intraperitoneal treatment of either
2.12Psel-Crry or 2.3Psel-Crry). Prior to surgical procedures for GMH induction, animal breeders
were randomly assigned to groups. Randomization was performed by an external lab personnel
and was dependent on liter sizes at P1 of life in order to satisfy the numbers across groups. To
minimize confounding variables and reduce model variability, a single lab person performed all
GMH-inducing injuries. To minimize confounders, a single lab person performed the treatments,
testing, and scoring and was blinded to group allocations for the duration of the study. All surgical
injections into the SVZ for GMH induction was conducted on post-natal day 4 (P4). Following

11

injection, pups were placed on a heating pad for 30 minutes, then reunited with the mother. The
total handling time of pups away from the mother was approximately 45 minutes. They were then
monitored for an additional 60 minutes to ensure care of the pups by the mother. Animals were
excluded if they died within 24 hours of surgery (<10% of animals). Study endpoints were P14
(10 days post-injury) for subacute outcome analyses, including histology and behavioral testing,
and P45 (41 days post-injury) for chronic outcome analyses, including animal survival, MR
imaging, and behavioral tasks.

Animal Husbandry and Care
The Institutional Animal Care and Use Committee (IACUC) at our institution approved all
animal rearing, care, and euthanasia procedures. Wild-type C57Bl/J mice (Jackson Laboratory,
ME, USA) were obtained at age P30 and acclimatized for 1 week prior to setting up. Animals were
then mated in pairs. Cages were cleaned weekly and bedding provided. All mice housed in the
facility were exposed to 12 hours light/dark cycles and received access to food and water ad
libitum, while pregnant females received a high fat diet as recommended by the institutional
veterinarian. All tests and experiments were conducted during the light cycle. Pregnancy and litter
checks were performed daily. Males were separated to another cage on day of injury due to
propensity of male mice to kill injured offspring. All animals were then returned to the mouse
housing facility.

Construction, Expression, and In Vitro Characterization of Recombinant Proteins
For construction of B.Psel scFv and NB.Psel scFV, total RNA was isolated from anti-Pselectin hybridoma cell lines 2.12 and 2.3, respectively, as described [34]. The 2.12 hybridoma
produces a mAb that blocks P-selectin adhesion function, whereas the mAb from the 2.3
hybridoma is non-blocking [35]. Using methods we have described [36], cDNA corresponding to
mRNA was synthesized, with primers for variable heavy (VH) and variable light (VL) chain
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domains. PCR products were cloned and positive colonies sequenced and aligned using NCBI
blast database. A second round of PCR was subsequently conducted to amplify VH and VL chain
cDNA, and a CD5 signal peptide sequence and a His tag (6X) sequence added to the 5’ end of
the VH chain, and a (Gly4Ser1)3 sequence was inserted between the VH and VL fragments. For
construction of the B.Psel-Crry and NB.Psel-Crry expression plasmids, each scFv sequence was
linked to the sequence encoding the extracellular region of mouse Crry (residues 1-319, Genbank
accession number NM013499) by overlapping PCR with the inclusion of a (G3S2)2 linker
sequence. The fusion constructs were cloned into the pEE12.4 expression vector (Lonza), and
expressed in Expi293 cells as described by the provider (ThermoFisher). After harvest, the
supernatant was filtered (0.22 µm) and protein purified using a His60 Nickle column (Clontech)
and subsequent filtration with 30 kDa MW cut-off with PBS buffer exchange. Proteins were stored
at -80C, and once thawed stored at 4C for up to 2 weeks. To note, we were unable to express
the scFv constructs alone (ie without fusion partner).
P-selectin binding of fusion proteins was confirmed by standard ELISA using recombinant
mouse P-selectin-Ig (BD Biosciences) as capture antigen and anti-His tag Ab (Clontech) for
detection (data not shown). Binding characteristics were analyzed by surface plasmon resonance
(SPR). For SPR binding assays, binding affinity (KD) and kinetic parameters ((Ka and Kd) were
determined using a recombinant mouse P-selectin ligand (Sinobiological) printed onto a bare
gold-coated (47 nm) PlexArray Nanocapture Sensor chip (Plexera Bioscience). Analyses were
performed by Creative Peptides (Shirley, NY) with real-time binding signals recorded and
analyzed by Data Analysis Module (DAM, Plexera, Bioscience, Seattle, WA), and kinetic analysis
performed using BIAevaluation 4.1 software (Biacore, Inc.). Complement inhibitory activity of
constructs was measured following purification and before each use by flow cytometric analysis
of complement deposition in a standard zymosan assay [37].
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Treatment Paradigm
Two treatment paradigms were utilized: a sub-acute timepoint treatment scheme (up to
P14) and a chronic timepoint treatment scheme (up to P45). The first treatment time point for both
always occurred 1 hour post injury (P4). The first IP injection of 2.12Psel-Crry, 2.3Psel-Crry, or
PBS for all treatments occurred on P4 one hour post injury. Animals were treated IP at 20 mg/kg
dosing unless otherwise stated. For the sub-acute timepoint treatment scheme, treatments were
administered at P4, P7, P10, P13 for a total of 4 doses. For the chronic timepoint treatment
scheme, additional injections were administered at P4, P7, P10, P13, and weekly thereafter up to
P41 for a total of 7 doses.

Germinal Matrix Hemorrhage Injury Model and Lesion Grading System
GMH injury model and lesion grading system was followed as previously described by
Alshareef et al. (2022) [14]. Briefly, Clostridium-derived collagenase (Type VII-S collagenase,
C2399-1.5 KU, Sigma-Aldrich) was injected into the subventricular zone of mouse pups at P4 to
induce direct spontaneous non-traumatic vessel rupture with intracerebral hemorrhage in the
region of the germinal matrix and SVZ. Sham PBS injections were performed to ensure that
hemorrhage was a result of collagenase injection and not from mechanical insertion of the needle.
Animals were sacrificed at P14 (subacute outcomes) and P45 (chronic outcomes). The animalspecific injury grading system was to establish a distinction between parenchymal injury,
ventricular involvement, and PHH. Grading scale system was followed as previously described
[14].
•

Scale 0 = No lesion or ventricular enlargement.

•

Scale 1 = Lesion volume <30% of hemispheric cortical tissue ipsilateral to injury site
without ventricular involvement.

•

Scale 2 = Lesion volume >30% of hemispheric cortical tissue ipsilateral to injury site
without ventricular involvement.
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•

Scale 3 = Lesion extending into the ipsilateral ventricle with no ventricular enlargement.

•

Scale 4 = Lesion extending into the ipsilateral ventricle coupled with unilateral
ventriculomegaly.

•

Scale 5 = Lesion extending into both ventricles resulting in bilateral ventriculomegaly,
global hydrocephalus.

Nesting Building
Nest building was performed as previously described by Deacon 2006 [38]. Briefly, test
mice are singly housed, and a new nestlet is introduced to the cage 1 hr before the active phase
(dark phase). The next morning, the remaining compacted cotton from the nestlet is weighted
(untorn nestlet), and the nests are scored on a rating scale of 1-5, with experimenter blinded to
genotype. A well-structured nest is scored 5 and failure to disturb the nestlet is scored 1.

Locomotor Activity
Test mice were placed in a clean home cage with minimal bedding inside the Photobeam
Activity System (San Diego Instruments), where 5 photobeams measure the mouse’s locomotor
activity in 5-minute bins. Activity was monitored over the course of an hour, and data is presented
as the total number of beam breaks.

Elevated Plus Maze
Mice were introduced in the center of the elevated plus maze (Stoelting #60140) in white
light (100 lux) and recorded for 5 minutes using ANY-maze behavior tracking software (Stoelting)
with center-point detection. Data are reported as the percent of time spent in the open areas.
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Three-Chamber Social Interaction (novel object vs novel mouse SI testing)
Mice were acclimated for 5 min in an open field arena (44 cm2) with 2 clear plexiglass
holding chambers on either side of the arena. After acclimation, test mice were removed from
arena, and a novel, conspecific mouse and a novel object (medium black paper binder) were
placed in either holding chamber. Test mice were returned to arena and recorded for 5 min using
Ethovision XT software (Noldus; RRID:SCR_000441). Interaction time is defined as time spent in
an 8 cm interaction zone around the holding chambers.

Fear-Conditioning
Fear conditioning was performed as previously described by Wehner and Radcliffe 2004
[39]. Briefly, test mice are placed in a fear conditioning chamber (MedAssociates) and allowed to
explore the arena for 3 min, after which a loud auditory stimuls (30 s; 90dB) that co-terminates
with a 2 s mild footshock (0.5 mA) is presented to the animal. This is repleated twice more, with
a 1 min interval seaparating the tones/shocks. After 24 hr, animals are retruned to the chamber,
and its behavior in the context, in a new contex, and with the audible tone played in a new context
is recorded by a videotracking system (Video Freeze V2.6; MedAssociates). Data are presented
as percent of time the mouse is immobile.

Ultrasonic Vocalization (USV) Recordings
Distress USVs were recorded from juvenile mice as previously described [40]. Briefly,
pups were recorded in a random order in a small, sound-attenuated chamber following separation
from dam and littermates. USVs were recorded for 3 min on post-natal days 5, 7, and 11 using
Avisoft UltraSoundGate equipment (UltraSoundGate 116Hb with Condenser Microphone CM16;
Avisoft Bioacoustics, Germany). USVs were analyzed using Avisoft SASLab Pro (Avisoft
Bioacoustics) using a 20 kHz cutoff.
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Tissue Processing and Histological Analyses
Animals in the subacute study were sacrificed at P14. Following euthanasia, cardiac
perfusion was performed with cold PBS followed by 4% paraformaldehyde mixed in PBS. Brains
were then carefully extracted and placed in 4% paraformaldehyde solution overnight at 4°C. The
brains were then moved to a new vial with 30% sucrose mixed with 4% paraformaldehyde in PBS.
For tissue cutting, the brains were embedded in Tissue-Plus Optimal Cutting Temperature (OCT)
compound (23-730-571, Fisher Healthcare) and frozen. At time of cutting, brains were cut in 40
µm coronal sections using a freeze-mount cryostat. The complete brain was collected in 12-well
plates kept in PBS-filled wells until histologic analysis. For Nissl staining, serial brain sections 200
µm apart were mounted on a slide and stained using cresyl violet as previously described [41].
For ventricular and lesion volume measurements, 8 serial Nissl-stained brain sections 200 µm
apart and 40 µm thick were used to reconstruct the total lesion volume. 4x magnification images
of each slice were acquired using a Keyence BZ-X710 microscope (Keyence Co., Itasca, IL,
USA). Blinded observers calculated the lesion and ventricular areas using NIH ImageJ (FIJI).

Immunofluorescence staining and imaging
Mid-hippocampal

and

mid-ventricular

regions

were

identified

by

stereometric

measurement using a mouse brain atlas, followed by standard immunofluorescent (IF) staining
as previously described [23]. All imaging and analysis were performed by a blinded lab personnel.
For microglial and complement IF staining analyses, high-resolution imaging was
performed using a Zeiss LSM 880 confocal microscope (Zeiss, Carl Zeiss Microscopy, LLC, White
Plains, NY, USA) at 40x with water-media overlay and using the Z-stacking feature for Iba and
C3 staining. Images were deconvoluted and reconstructed in 3D plane using Imaris Microscopy
Image Analysis Software. Mean Fluorescent Intensity of 3D reconstructed image was quantified
as total voxel number.
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For P-selectin analyses, 20x images of each slice were acquired using a Keyence BZX710 microscope specifically at periventricular, hippocampal, and white matter brain regions
(Keyence Co., Itasca, Il, USA). Images were calculated as the total integrated density (product of
Area and the average signal intensity per pixel as a Mean Gray Value) using NIH ImageJ.
All staining was performed with negative control images (secondary antibodies only) in
order to correct for underlying auto-fluorescence. Fluorescence-based analysis was performed
rather than cell counting due to high cell density and clumping in the proximity of the injury site.
Primary antibodies used for staining were: anti-C3 (Abcam, Cat. #: ab11862, 1:200), anti-NeuN
(Abcam, Cat. #: ab104225, 1:200), and anti-Iba1 (Invitrogen, Cat. #: PA5-21274, 1:80).
Secondary antibodies utilized were all donkey and include anti-rabbit Alexa Fluor 488 nm
(Invitrogen, Cat. #: A-21206, 1:200), anti-rat Alexa Fluor 488 nm (Invitrogen, Cat. #: A-21208,
1:200), anti-rat Alexa Fluor 555 nm (Abcam, Cat. #: ab150154, 1:200), anti-rabbit Alexa Fluor 555
nm (Invitrogen, Cat. #: A-31572, 1:200), anti-goat Alexa Fluor 647 nm (Invitrogen, Cat. #: A32849,
1:200).

Tail Clipping Assay
Cohort of each treatment group followed the sub-acute treatment scheme up to P13. Tail
bleed time in P13 C57BL/6J pups were measured 2 hours after their designated final treatment
of PBS, 2.3Psel-Crry, or 2.12Psel-Crry, as described by Zheng et al (2021) [32]. Briefly, pups
were anesthetized with ketamine/xylazine mix and were placed in a prone position and a distal
5mm segment of the tail amputated. The tail was immediately immersed in pre- warmed isotonic
saline at 37°C and each animal monitored till cessation of bleeding. If bleeding on/off cycles
occurred, the sum of bleeding times within the 20-minute period was used.

Platelet interaction Flow Cytometry
Blood was collected from the mice by cardiac puncture at sacrifice in 50mM EDTA and
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Futan-75 to prevent complement activation. Collected samples were spun down for 10 min at
100g. Supernatant was then removed and the pellet was resuspended in 1 mL of citrate buffer
containing 50 ng/mL PGE2 to prevent platelet activation. The resuspended samples were spun
down for 10 min at 3,200g. Supernatant was then removed and the erythrocytes lysed using the
ACK buffer (ACK Lysing Buffer, Gibco, ThermoFisher Scientific) for 4 minutes. The samples were
then washed with PBS for 10 min at 3,200g. Supernatant was removed and samples containing
circulating immune cells and platelets were resuspended in FACS buffer, incubated with anti-FcR
antibody (clone 24G2) and stained with the following primary antibodies: Ly6G (clone 1A8), Ly6C
(clone AL-21), CD11b (clone M1/70, eBioscience), CD62P (clone RB40.34) and CD41 (clone
MWReg30). All antibodies were purchased from BD Pharmingen unless otherwise specified. After
staining samples were washed twice in FACS buffer, fixed for 10 minutes at 4°C in 2%
paraformaldehyde, washed and resuspended in FACS buffer. The samples were acquired on a
Fortessa (BD Pharmingen) and analyzed with FlowJo software (TreeStar).

Cell Quantification Flow Cytometry
Animals were sacrificed at P14 for tissue collection. Following euthanasia, cardiac
perfusion was performed with cold PBS only. Brains were then carefully extracted and directly
placed in liquid nitrogen and placed in –80°C until ready to use. The tissue was homogenized and
a cocktail of phosphatase and protease inhibitors were implemented. Collected samples were
stained following similar procedures as platelet interaction flow cytometry. The samples were
acquired on a Fortessa (BD Pharmingen) and analyzed with FlowJo software (TreeStar).

Tissue Preparation for Multiplex Assay
Animals were sacrificed at P14 for tissue collection. Following euthanasia, cardiac
perfusion was performed with cold PBS only. Brains were then carefully extracted and directly
placed in liquid nitrogen and placed in –80°C until ready to use. The tissue was homogenized and
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prep for assay using RIPA buffer and a cocktail of phosphatase and protease inhibitors as
instructed by Eve Technologies (Calgary, AB Canada). The total protein concentration of each
sample was normalized to 20 ug by performing a BCA assay. Prepared brain tissue homogenate
was then sent to Eve Technologies following their shipping instructions. The multiplex panels
utilized were Mouse Cardio Panel 1 and Mouse focused 10-Plex Discovery Assay.

Statistical analysis
Experimental sample size was determined using Power analysis and sample size
estimation, performed through G*Power 3.1.9.2 tool (Franz Faul, Kiel University, Germany).
Barnes maze performance was chosen as a reference test to calculate the effect size (Estimated
mean and SD). Higher or comparable effect size was also expected for the remaining tests. A
calculated effect size (d) of 2.0 was anticipated when comparing GMH mice to naïve and 1.6 when
comparing vehicle to CR2Crry in the treatment group based on our preliminary studies with GMH.
Therefore, we used an effect size of 1.6 for our power analysis for these aims. Two-tailed analysis
with significance level α = 0.05 was considered and then a corrected αc = α/(number of primary
comparisons)=0.05/(2 primary comparisons)= 0.025. Ratios of group numbers was considered to
be 1 (N1/N2) with equal number of mice per group. The result of analysis reveals a sample size
of 8 evaluable mice per group with an actual computed power of 84%. To ensure sufficient number
of evaluable animals is available, we corrected for potential 40% mortality/exclusion of animals in
all studies. Thus, a final number of 12 animals would be required per experimental group to satisfy
the necessary minimum. Finally, in order to maintain animal litter continuity, litters were
randomized into experimental groups rather than individual pups. All statistical analyses were
performed using GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA).
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Chapter 3.

P-selectin and Complement Have Roles in Exacerbating the Acute

Pathophysiological Sequelae Post-GMH
3.1 Background and Introduction
Germinal Matrix Hemorrhage (GMH) is a devastating disease in the neonatal population
that is caused by disruption of fragile vasculature within the subventricular zone (SVZ). GMH often
leads to the development of intraventricular hemorrhage (IVH), defined by bleeding into the
ventricular system, resulting in two common pathological progressions, post-hemorrhagic
hydrocephalus (PHH) and periventricular leukomalacia (PVL) that negatively impacts
neurodevelopment. Similar to other brain injuries, GMH involves an unpredictable primary insult
that is followed by a secondary injury that is induced by a neuroinflammatory response.
A central component of inflammatory responses, as it plays a role in both innate and
adaptive immune responses, is the complement system. Downstream cleavage of C3 protein
leads to the production of opsonization fragments (C3b, iC3b, C3d, C3dg), as well as the
anaphylatoxin C3a. Further downstream cleavage within the cascade produces additional
fragments (C5a, C5b, C6-9) leading to additional opsonization, immune cell recruitment, and
formation of the cytolytic membrane attack complex (MAC).
Complement has previously been implicated in the acute pathophysiological sequelae of
the secondary injury response in GMH and PHH. Additionally, cell adhesion molecules (CAM)
such as P-selectin are known to have important roles in immune cell infiltration, a physiological
process that is known to influence injury and inflammation. Both complement and P-selectin
blockade have been implicated to be protective in various intracranial hemorrhage (ICH) models.
Furthermore, complement activation products can upregulate P-selectin expression, and Pselectin can directly activate complement. Therefore, giving investigative interest into novel
therapeutics that inhibit such mechanisms in propagating inflammation in GMH and the
pathological sequalae that follow.

21

Provided clinical and pre-clinical data involving complement and P-selectin’s role in GMH
pathology and their role in inflammation, we sought to establish the effect of complement inhibition
via inhibition of C3 convertase by using novel P-selectin targeted complement inhibitors as well
as investigate the therapeutic benefits of blockading P-selectin functionality in reducing the
secondary inflammatory response and its progression of PHH. Following GMH induction, animals
were treated via IP injections with PBS (vehicle) or with either 2.12Psel-Crry or 2.3Psel-Crry at
20 mg/kg. Animals then followed a sub-acute treatment paradigm up to P14 at which point brain
histology and the inflammatory profiles of the animals were evaluated to determine the
effectiveness of each inhibitor in minimizing the effects of complement proteins and neutrophil
infiltration on progressing the secondary inflammatory response.
Additionally, previous work from Zheng et al (2021) [32] demonstrated that the use of the
novel P-selectin targeted complement inhibitor that contained dual functionality in inhibiting
neutrophil recruitment (2.12Psel-Crry), also inhibited the coagulation cascade. Therefore, in
addition to interrogating the effectiveness of the inhibitors in immune cell recruitment and
inflammation, it was of interest to analyze the coagulative state after treatment. A separate cohort
following GMH induction followed a sub-acute treatment paradigm up to P14 at which point
heterotypic platelet interactions and immune cell localization were evaluated via flow cytometry.
An additional cohort following GMH induction, followed a sub-acute treatment paradigm up to P14
at which point bleeding time was evaluated between each treatment group.
Aim 1 is focused on testing the hypothesis that P-selectin and complement have roles in
exacerbating the acute pathophysiological sequelae post-GMH in a neonatal murine model. To
test this hypothesis, I investigated each Psel-Crry construct’s ability to limit the pathological
progression of GMH and its sequalae as well as investigated the mechanistic effect of the PselCrry constructs.
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3.2 Results
Using our recently developed neonatal murine GMH model, Nissl staining was conducted
to measure severity of hydrocephalus development post-GMH injury at P14. Following GMH, 61%
of vehicle treated animals developed Grade 5 global hydrocephalus compared with only 11% of
animals treated with 2.3Psel-Crry (Figure 1a). Surprisingly, 73% animals treated with 2.12PselCrry (which also directly blocks P-selectin mediated adhesion) developed Grade 5 global
hydrocephalus (Figure 1a). Additionally, lesion and ventricular volumes of each group was
quantified using a serial of Nissl-stained sections. Both ventricle and lesion volumes were reduced
with 2.3Psel-Crry treatment compared to vehicle (Figure 1b,c). Treatment with 2.12Psel-Crry
resulted in a significant reduction in ventricular and lession volumes compared to vehicle, but
significantly larger ventricular and lesion volume compared to Naïve and 2.3Psel-Crry treated
animals. There was no significant difference between the Naïve vs sham (PBS in place of
collagenase injection) groups (Figure 1b,c), providing evidence that the GMH induced injury was
not simply the result of a mechanical injury, but due to collagenase causing the rupture of the
vasculature.
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To characterize the inflammatory response following GMH, various analyses were
conducted via flow cytometry, chemokine/cytokine multiplex assays, and immunoflourescence
imaging. To analyze the effect that each treatment had on immune cell recruitment in
exacerbating inflammation, a cohort of each experimental group was examined following the P14
sub-acute treatment scheme. At time of sacrifice, whole brains were collected and homogenized
and various markers used to assess immune cell populations via flow cytometry. Compared to
vehicle treated mice, there was a trend toward a reduction in macrophages and microglia in brains
from animals treated with 2.12Psel-Crry (Figure 2a: p<0.41195 and p<0.6419, respectively).
Furthermore, there were no significant differences in B or T lymphocyte populations in mice
treated with vehicle vs. 2.12Psel-Crry (Figure 2b). In contrast, 2.3Psel-Crry treatment resulted in

a significant increase in B cells, macrophages and microglia compared to vehicle (Figure 2a,b).
Of note, there was no significant difference in numbers of live cells across all groups, but a
significant decrease was observed in non-immune cells in 2.3Psel-Crry treated mice, but not in
2.12Psel-Crry mice when compared to vehicle (Figure 2c).
To further analyze the effect that each treatment had on an inflammatory responses, a
additional cohort from each experimental group was examined following the P14 sub-acute
treatment scheme. At time of sacrifice, whole brains were collected and homogenized and various
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inflammatory cytokines and chemokines quantified via multiplex assay. Animals treated with
2.12Psel-Crry displayed a significant decrease in IL-12p70 compared to vehicle and 2.3Psel-Crry
treated animals (Figure 3a,b). Treatment with 2.12Psel-Crry showed a trend toward reduced IFNgamma (p<0.5956), IL-1beta (p<0.9512), IL-2 (p<0.55), MCP-1 (p<0.7273), and TNF-alpha
(p<0.9903) when compared to vehicle (Figure 3c,d,e,f).
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P-selectin expression marks a site of inflammation, and P-selectin expression was
analysed within periventricular tissue, hippocampal tissue, and white matter following GMH
induction. For analysis of P-selectin expression, brain sections from P14 mice were stained for Pselectin (CD62p) by IF and expression quantified in each specific brain region (Figure 4a). PostGMH, P-selectin expression was evident along the lesion border of ipsilateral ventricles as well
as in white matter tracts such as the corpus callosum (Figure 4b,c). This finding also provides
justification for utilizing a P-selectin targeting vehicle for site-targeted complement inhibition in the
setting of GMH. Furthermore, both 2.12Psel-Crry and 2.3Psel-Crry treatment resulted in a
significant decrease in P-selectin expression. There was no significant difference between naïve
and sham (Figure4d,e,f).
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Complement activation has been linked to microgliosis, and studies have shown an
aberrant process of microglial phagocytosis of complement opsonized neurons and synapses in
certain pathological CNS conditions [14, 42]. Therefore I investigated the impact of our targeted
complement inhibitors on microglial recruitment and activation. For analysis of microgliosis and
its relationship with complement, brain sections from P14 mice were stained for Iba-1 (microglia
marker)

in

the

periventricular

and

hippocampal
regions

brain

(Figure5a).

Imaris analysis of MFI
from 3D reconstructed
images

showed

a

significant decrease in
periventricular
microglia with 2.3PselCrry or 2.12Psel-Crry
treatment, and with
2.3Psel-Crry having a
more significant decrease (Figure5c). There was no significant decrease in microglial presence
within the hippocampus with 2.3Psel-Crry or 2.12Psel-Crry treatment (Figure5d). Furthermore
microglial presence correlated with C3 deposition within similar perilesional and hippocampal
brain regions (Figure5b). Within both perventricular and hippocampal regions, treatment with
2.3Psel-Crry resulted in a significant decrease in C3 deposition (Figure5e,f). In comparision,
treatment with 2.12Psel-Crry resulted in similar decreased C3 deposition within the periventricular
regions (Figure5e), but the difference in the hippocampal brain region did not reach significance
(Figure5f).
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Thus, while the 2.3Psel-Crry targeted complement inhibitor significantly reduced infarct
size and reduced post-hemorrhagic hydrocephalus (PHH), 2.12Psel-Crry failed to provide
protection and outcomes were similar or worse as compared to vehicle. To better understand
this unexpected outcome, further studies were carried out to investigate the phenotypic and
mechanistic effect of the Psel-Crry constructs. Cohorts were subject to the sub-acute treatment
scheme, and following their fourth treatment on P13 were analyzed for bleeding time using a tail
clip assay. Animals treated
with

2.12Psel-Crry

significantly

had

increased

bleeding times compared to
all other groups, providing
evidence
with

of

the

cascade

interference
coagulation

(Figure6a).

To

investigate further, a cohort

of each treatment group
was subject to the sub-acute treatment scheme and sacrificed at P14, at which point whole blood
was collected and prepped for flow cytometry analyses of P-selectin interactions with monocytes
and

neutrophils.

2.12Psel-Crry

treatment

resulted

in

a

significant

decrease

in

CD41+CD62p+Ly6G+ populations as well as CD41+CD62p+Ly6C+ populations when compared to
2.3Psel-Crry treatment (Figure6b). These findings provide evidence that 2.12Psel-Crry, but not
2.3Psel-Crry, reducte

heterotypic platelet interactions (platelet-neutrophil and platelet-

monocyte) which can play a role in clot formation.
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3.3 Discussion
GMH is a hemorrhagic event in neonates that is characterized as having a primary insult
that is untreatable followed by a progressive secondary injury. While the primary insult is
unpredictable and untreatable it has been of high therapeutic interest to understand the
mechanistic initiation and propagation of the progressive secondary injury, such as the onset of
post-hemorrhagic hydrocephalus. Previous explanations identify obstruction of ventricular
absorption pathways as well as iron exposure to be suspecting contributors [43]. Studies have
shown evidence that iron exposure within the ventricles following red blood cell lysis leads to an
inflammatory response and development of hydrocephalus [44-47]. Iron chelation as a form of
therapy to limit PHH development has been of high interest in the past decade. Another potential
therapy involves the use of minocycline, a potent microglial inhibitor. Multiple preclinical studies
have shown the potential efficacy of minocycline as a therapeutic [48, 49]. However, a recent
clinical study with minocycline in a neuroinflammatory disease in an at-risk population showed no
neuroprotective effects, and in fact reported some serious adverse events [50]. From a more
mechanistic standpoint, additional work has provided evidence that PHH development is
characterized by an increased inflammatory responses post-GMH, leading to hypersecretion of
CSF by the choroid plexus, the recruitment of inflammatory cells, and increased recruitment of
astrocytes [51-53].
Only recently has the complement pathway been implicated in playing a role in post-GMH
sequalae and propagation of PHH. Complement, in the setting of GMH and neonatal hypoxicischemic brain injury, has been shown to lead to increased recruitment of microglia, increased
recruitment of astrocytes, neuronal engulfment, and development of PHH [14, 54, 55]. More
specifically, the C3 anaphylatoxin (C3a) has been shown to play a role in periventricular microgliaastrocyte interactions [55], a finding further supported by work from our lab demonstrating that C3
convertase inhibition causes a reduction in astrocytosis and microgliosis leading to
neuroprotective effects and reduced PHH development [14]. Given the lack of treatment options
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for GMH secondary injury and the recent evidence of complement’s role in propagating such
injury, it is of high clinical relevance to explore relevant target strategies and further elucidate the
mechanistic pathology of secondary GMH injury. In this study, we investigated a novel strategy
to target complement inhibition specifically to sites of P-selectin expression, a relevant adhesion
molecule at sites of vascular injury/inflammation, as well as investigated P-selectin’s involvement
in leukocyte recruitment in propagating GMH secondary injury. The complement inhibitors used
were anti-P-selectin single chain antibodies (scFv) linked to Crry, a C3 convertase inhibitor. One
of the scFv targeting vehicles (2.12scFv) additionally blocked the cell adhesion site of P-selectin,
whereas the other (2.3scFv) bound P-selectin without blocking its function.
Given the role of P-selectin in the primary phase of neutrophil infiltration, an early event
that can lead to the propagation a secondary inflammatory response, it was expected that
treatment with 2.12Psel-Crry (blocking construct) would be neuroprotective and reduce PHH
occurrence. However, 2.12Psel-Crry treatment resulted in similar or worse outcomes compared
to vehicle. In contrast, we see a marked reduction in injury grade, ventircular volume, and lesion
volume when GMH animals are treated with 2.3Psel-Crry (non-blocking construct). While
2.12Psel-Crry resulted in worse outcomes, it did lead to a significant decrease in the presence of
macrophages and microglia within homogenized brain tissue, as well as a significant decrease in
IL-12p70. IL-12p70 is produced mainly by macrophages and dendritic cells, and is known to play
roles in Th1 cell differentiation and proliferation as well as induction of IFN-gamma production.
This may also be an explanation of the significant decrease in IFN-gamma when comparing
2.12Psel-Crry with 2.3Psel-Crry. Furthermore, while the other cytokines and chemokines were
not significatly different across the experimental group there was a trending decrease in IFNgamma, IL-1beta, IL-2, MCP-1, and TNF-alpha. A number of studies have found changes in
these specific cytokines and chemokines in CSF levels in the setting of experimental or human
PHH [16, 56], therefore providing evidence for the need to further investigate complement
inhibition’s effect on cytokines and chemokines in PHH.
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Astrogliosis and microgliosis are canonical functions that are crucial for proper
homeostatic functions such as clearence of pathogens and cellular debris, but also contribute to
neuroinflammatory activation and progression [57, 58]. In addition, studies have shown that the
complement system plays a crucial role in microgliosis and have identified a process of
complement mediated phagocytosis of neurons by microglia [14, 42]. Furthermore, activatied
microglia in turn have been found to perpetuate inflammatory responses by further activating
neurotoxic reactive astrocytes [59] . Immunofluorescent imaging and analyses showed a
correlation of C3 deposition with microgliosis occurrence post-GMH. These findings of microglial
recruitment and activation were correlated with increased complement deposition, and
complement inhibition with either of the Psel-Crry constructs resulted in decreased recruitment
and activation of glial cells.
The current study shows that following GMH, there is a significant increase in P-selectin
in the periventricular region, hippocampal region, and white matter. This provides evidence that
the secondary inflammatory response following GMH involves the recruitment and infiltration of
leukocytes to these brain regions, specifically neutrophils that interact via PSGL-1. A recent study
involving the neuroinflammatory pathology of multiple sclerosis identified increased and
preferential expression of P-selectin within the white matter, and reported a positive correlation of
its expression with clinical outcome severity [60]. Both 2.3Psel-Crry and 2.12Psel-Crry treatment
resulted in a trend toward decreased P-selectin expression in all three brain regions. This can be
accounted for in part by the relationship between P-selectin and complement, and since localized
inhibition of complement has been shown to results in a reduction in P-selectin expression [31].
While both constructs were able to limit P-selectin expression, 2.12Psel-Crry did not improve
outcome compared to vehicle. The reason for this was further investigated, and we provide a
potential explanation by showing that 2.12Psel-Crry interfered with coagulation, which is not
desirable for a hemorrhagic condition. Further investigation showed that 2.12Psel-Crry caused a
marked decrease in heterotypic platelet-leukocyte interactions. Previous studies show that
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platelets have distinct roles in thrombogenic and inflammatory activity, and that the interaction of
homotypic platelet interactions (platelet-platelet) as well as heterotypic platelet interactions
(platelet-leukocyte) play an important role in the pathophysiological link between inflammation
and thrombis [61, 62]. Thus, our data provides an explanation of why the blocking of Pselectin:PSGL1 interactions by 2.12Psel-Crry (but not by 2.3Psel-Crry) lead to worse outcomes
since GMH is a hemorrhagic pathology.
In summary, we show that P-selectin targeted complement inhibition via 2.3Psel-Crry
leads to a reduction in hydrocephalus occurrence, ventricular volume, lesion volume, and
microgliosis. These data provide strong evidence of a role for complement in the initatiion and
propagation of secondary injury post-GMH. The data further show that complement inhibition, and
specifically a humanized equivalent of 2.3Psel-Crry has great potential in limiting GMH pathology.
The data also show that the dual function site-targeted complement inhibitor 2.12Psel-Crry,
posesses additional anti-inflamatory activities that result in interefernce with thrombosis and that
suggests this type of inhibitor has potential for treating conditions that include thrombotic
pathologies, such as ischemic stroke. On a translational note, the 2.3Psel and 2.12Psel scFv
targeting vehichles recognize both mouse and human P-selectin, and the human ortholog of Crry
is CR1, which has been shown to be safe in humans when used as an untargeted construct.

Chapter 4. Complement inhibition following GMH improves cognitive outcomes in
adolescence
4.1 Background and Introduction
Two pathological progressions commonly occur

after GMH: post-hemorrhagic

hydrocephalus (PHH) and periventricular leukomalacia (PVL). PHH is the result of progressive
dilation of the cerebral ventricular system due to disturbances in cerebrospinal fluid (CSF) flow or
absorption following hemorrhage. PVL involves the softening and degeneration of white matter
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that surrounds the lateral ventricles. Both sequalae negatively impacts neurodevelopment and
are strongly associated with increased risk of cerebral palsy (CP). Furthermore, In addition to
complement being implicated in acute pathologic development, it has been found to play a role in
exacerbating neuroinflammatory responses and pathology at chronic timepoints in adult brain
injuries. Therefore, it is of high relevance to determine how Psel-Crry impacts the development of
these pathological processes and their effect on neurodevelopment. Of note, due to the negative
outcomes found at P14 when treated with the dual functioning inhibitor, 2.12Psel-Crry, only
2.3Psel-Crry was investigated in this aim which measures outcomes at a chronic timepoint.
This aim is focused on testing the hypothesis that P-selectin and complement dependent
pathological outcomes correlate with decreased cognitive outcomes and development of PHH.
To test this hypothesis, I investigated 2.3Psel-Crry’s effect on motor and cognitive function as well
as investigated its effect on PHH development and white matter protection.

4.2 Results
Following GMH induction, animals were treated via IP injections with PBS (vehicle) or with
2.3Psel-Crry at 20 mg/kg. Animals then followed a chronic treatment paradigm up to P45 (see
methods) during which time imaging data was collected and behavioral tasks were performed.
Specifically, magnetic resonance imaging (MRI) was performed at P30, and the cognitive tasks
of nest building task, locomotor activity, elevated plus maze, 3-chamber social interaction, and
fear conditioning were performed between P39-44.
Treatment with 2.3Psel-Crry showed improvement in survival outcome compared to
vehicle (Figure 7a). The decline in animal survivability begins in vehicle as early as P21, the
timepoint at which they are weaned and become self-dependent. Beginning at P34 up to P45,
there is a sharp decrease in vehicle survival involving an approximate 30% decrease in probability
of survival. This is in comparison to 2.3Psel-Crry treated with an approximate 15% decrease
between P34 and P45. In correlation with survival rate, MR imaging was utilized to better
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characterize PHH development and preservation of white matter. Imaging at P30 showed vehicle
resulting in 64.71% developing hydrocephalus (Figure 7b,c). This was in comparison to 2.3PselCrry treated that resulted in approximately 37% developing PHH. Furthermore, there was a clear
phenotypic distinction in preservation of white matter, specifically the corpus callosum and
hippocampus, as seen in MR imaging that was correlative to PHH occurrence (Figure 7c).
With an ongoing neuroinflammatory response and expected loss of neurons after GMH
[14], animals were subjected to a battery of cognitive and motor tasks to determine whether
complement inhibition functions as a neuroprotective agent at a chronic timepoint. Nest building
is a social and cognitive task that can be assessed to analyze changes in common social practices
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as well as cognitive and motor function by their ability to build the nest. Compared to naïve, vehicle
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treated animals performed significantly worse in this task (Figure 8a,b). In Comparison, 2.3PselCrry treated animals showed a significant increase in performance that was similar to naïve.
Anxiety and stress were assessed with the elevated plus maze. The vehicle treated group showed
increased exploration of the open arms as shown by a significant increase in overall percent of
time spent in the open arms compared to naïve and 2.3Psel-Crry treated animals (Figure 8c).
2.3Psel-Crry treated animals showed a significant decrease in percent time spent in the open arm
compared to vehicle and was similar to naïve outcomes. Additionally, the sham group performed
similar to naïve providing evidence to support the concept that germinal matrix rupturing and postGMH inflammation contributes to deteriorating cognitive abilities, rather than mechanical injury
alone. In addition to EPM task, stress and anxiety was characterized by ultrasonic vocalizations
of each experimental group at an early timepoint when removed from mother and littermates. At
P5, P7, and P11 the number of calls were accounted for and showed a significant increase within
vehicle, while 2.3Psel-Crry treatment resulted in a significant decrease (Figure 8d).
In a social interaction test, with the presence of a competing novel inanimate object, there
were no social variations among all four experimental groups (Supp Fig.1). Hippocampal integrity
and amygdala function was assessed via fear-conditioned memory retention with contextual and
cued fear learning. When re-exposed to the shock environment (contextual stimulus), vehicle
treated mice spent significantly less time freezing when returned to the shock environment
compared to naïve mice (Figure 8e). 2.3Psel-Crry treated mice showed a trend toward performing
similar to naïve but was not significant (Figure 8f). Analyses of amygdala function via presentation
of the tone cue (conditioned stimulus) showed vehicle treatment resulted in a less significant
amount of time freezing compared to naive (Figure 8i,j). Furthermore, conditioned stimulus
learning showed the 2.3Psel-Crry treated mice had similar freezing times as Naive, indicating that
2.3Psel-Crry helps preserve neurocognitive ability and memory function (Figure 8h,j).
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4.3 Discussion
Common pathological sequalae brought on by the secondary injury involve PHH and PVL
development, both of which results in major cognitive impairment. This has been shown in multiple
clinical and pre-clinical studies where premature neonates who have clinical grades 3-4
intraventricular hemorrhage have a direct relation to cerebral palsy (CP) development and drastic
mental deficits, even those with clinical grades 1-2 are at risk for developmental disability [63-66].
Previous studies in traumatic brain injury and stroke have shown that complement-mediated
neuroinflammation involves an ongoing expansion chronically that is correlated with ongoing
cognitive decline [20, 23, 33]. In the current study we show that secondary injury post-GMH
involves a continuous progression of the neuroinflammatory response leading to the development
of PHH and PVL in which complement is a key mediator in the initiation and propagation of, and
provides a mechanistic explanation of cognitive impairment,
Complement inhibition with 2.3Psel-Crry resulted in a reduced occurrence of PHH as well
as a retention in total white matter, which as expected resulted in improved neurocognitive
outcomes compared to vehicle. Nest building is a behavioral task dependent on limbic function
and resembles daily living activities that may be altered in patients with cognitive impairment [38,
67]. Surprisingly, there was a marked recovery in mice treated with 2.3Psel-Crry, with
performance similar to that in naïve mice. These data provide evidence that complementdependent secondary injury is progressive and induces profound chronic alterations resulting in
cognitive dysfunction which are reversible by complement inhibition with 2.3Psel-Crry. Our
analyses from elevated plus maze data further links cognition with progression of secondary injury
as determined by a reduction in stress and anxiety in animals treated with a complement inhibitor.
The last piece of evidence to characterize stress and anxiety within secondary injury pathology
was provided by the resolution of hyper-vocalization in 2.3Psel-Crry treated animals compared to
vehicle.
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In addition to observing cognitive abilities, a variation of the 3-chamber social interaction
involving a novel mouse and a competing novel inanimate object was utilized to identify changes
in social behavior during secondary injury progression and the effect of complement inhibition.
Interestingly, there was no variation in social behavior across all experimental groups. It is well
established, pre-clinically and clinically, that PHH affects development of the prefrontal cortex, a
brain region responsible for social behavior, and given the minimal effects of PHH on the
development of social behavior shown in this study, will require further characterization of the
secondary injuries effect by means of additional social behavioral tasks to draw significant
conclusions.
Finally, hippocampal integrity and amygdala function was assessed via fear-conditioned
memory retention with contextual and cued fear learning. As expected, due to the loss of white
matter as quantified by MR imaging, vehicle treatment resulted in a significantly lower retention
of both contextual and cued memory. Behavioral testing via contextual fear learning shows
hippocampal functionality was drastically decreased in vehicle treated animals, whereas
treatment with 2.3Psel-Crry trended toward evidence of its ability to rescue tissue as seen by
secondary injury. This was correlative of the MR imaging outcomes, with complement inhibitor
treatment providing retention of white matter. Lastly, behavioral testing via cued fear learning
showed when compared to vehicle, 2.3Psel-Crry had similar outcomes as naïve providing
evidence of the retention of amygdala functionality in fear memory. This finding was further
supported by vehicle having a less significant memory capacity of the conditioned stimulus.
With the evidence provided in aim 2, we show complement as being an influencer in the
chronic progression of the neuroinflammatory response and progression of secondary injury postGMH. Furthermore, we show that treatment with 2.3Psel-Crry limits the secondary injury at a
chronic timepoint as demonstrated by a decrease in PHH occurrence and the preservation of
neurocognitive function. More specifically, we saw preservation in normal social and cognitive
abilities of daily tasks, lower stress and anxiety, and intact hippocampal and amygdala function
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when treated with 2.3Psel-Crry. These behavioral outcomes correlated with tissue preservation
in cortical tissue, and thus provides a likely explanation for the rescuing of neurocognitive
impairment in GMH animals. Together, the evidence provided in aim 2 indicates an important role
for complement in the initatiion and propagation of secondary injury post-GMH, and that inhibition
of complement with 2.3Psel-Crry, or rather a human equivalent, has potential for limiting GMH
pathology.
Chapter 5. Final Discussion
5.1 Conclusion and Significance
Complement is garnering increasing interest for its role in canonical neurodevelopmental
processes and in pathologies of the brain. Since GMH is the most common neurologic pathology
in neonates and has no current treatment for its pathological sequalae, it is of high clinical interest
as a potential target of complement inhibition. This study provides further evidence of the proinflammatory effects of GMH contributing to worsened outcomes and development of
hydrocephalus. The study also provides evidence that these effects can be successfully mitigated
by P-selectin targeted complement inhibition via 2.3Psel-Crry, which represents a novel
therapeutic strategy for GMH and the pathology that follows.
Although unexpected, the worsened outcomes with a targeted construct that also inhibits
P-selectin function (2.12Psel-Crry) was explained by its effect on interfering with the coagulation
cascade. The study characterizes the potential mechanistic effects of the dual functioning
complement inhibitor and brings to light complement and P-selectin’s role in the onset of
inflammatory (immune cell infiltration) and hemodynamic (coagulation) effects in the
pathogenesis of this condition. This study also highlights the potential of a 2.12Psel-Crry type
construct as a therapeutic in non-hemorrhagic cerebrovasculature injuries.
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5.2 Future Directions
With the characterization of the hemodynamic effects of the dual functioning inhibitor
(2.12Psel-Crry), it is clear that it has promising potential in the setting of non-hemorrhagic
cerebrovasculature injuries, such as ischemic stroke. Of relevance, previous studies have
shown an important role for complement in the pathology of ischemic stroke [68]. Furthermore,
while the evidence provided in this study show that the 2.12Psel-Crry causes interference in
coagulation and was explained by a significant decrease in heterotypic platelet interactions, it is
of investigative and clinical interest to understand the exact mechanism as to how the
heterotypic interactions are interrupted. It is established that a critical mediator involved in
coagulation in the setting of P-selectin and PSGL-1 involves the circulating microparticle protein,
tissue factor. Tissue factor plays a critical role in the initiation of thrombin formation from
prothrombin, acting as the primary initiator of blood coagulation, and even more interestingly a
previous study has found that accumulation of tissue factor that begins the initiation of
coagulation is dependent upon microparticle PSGL-1’s interaction with P-selectin’s on platelets
[69, 70]. It is therefore of interest to explore the effects of 2.12Psel-Crry on tissue factor and
how this could influence the interference in heterotypic platelet interactions between Pselectin:PSGL-1 or vice versa, the platelet interaction’s influence on tissue factor.
With respect to a separate future direction within the setting of GMH, the complement
cascading system is quite complex with multiple proteins involved. To better understand the
mechanistic impact complement has on the propagation of secondary injury and the
pathological sequalae that follows GMH, it is of interest to further delineate the activation
pathways and effectors molecules that have pathological roles. Further studies should
investigate roles that the classical, alternative and lectin pathways of activation, as well as the
effects of downstream complement activation products C3a, C3 opsonins, C5a and C5b-9.
Specific targeting of a pathway or an activation product involved in this pathology could result in
a more effective as well as safer therapeutic strategy.
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